<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The incretin hormones glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 and <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent insulinotropic <z:chebi fb="7" ids="16670">peptide</z:chebi> are secreted by enteroendocrine cells and augment <z:chebi fb="105" ids="17234">glucose</z:chebi>-induced insulin secretion in response to food ingestion in a <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent manner </plain></SENT>
<SENT sid="1" pm="."><plain>This mechanism forms the basis for incretin-based therapies in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>However, the insulinotropic effect of incretins is diminished in type 2 diabetic patients, due in part to reduced expression of incretin receptors as a consequence of glucotoxicity </plain></SENT>
<SENT sid="3" pm="."><plain>In this issue of Diabetologia, Kang et al (DOI: 10.1007/s00125-012-2776-x ) provide evidence that in addition to glucotoxicity, lipotoxicity also affects incretin receptor expression and signalling in insulin-secreting cells and isolated islets </plain></SENT>
<SENT sid="4" pm="."><plain>In animal models of <z:mp ids='MP_0002055'>diabetes</z:mp>, the authors show that co-administration of a <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering drug with a dipeptidyl peptidase-4 inhibitor or a glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 agonist <z:mp ids='MP_0005292'>improved glucose tolerance</z:mp> and beta cell mass </plain></SENT>
<SENT sid="5" pm="."><plain>These novel findings provide convincing support for the notion that restoring <z:mpath ids='MPATH_458'>normal</z:mpath> circulating <z:chebi fb="23" ids="18059">lipid</z:chebi> levels in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> might help improve the efficacy of incretin-based therapies </plain></SENT>
</text></document>